Turning on tumor-fighting T-cells. Two signals are better than one when it come to developing new cancer therapies.
Edgington
S M
SM
D000069594:Abatacept; D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000276:immunology; D018122:B7-1 Antigen / Q000235:genetics / Q000276:immunology; D018106:CD28 Antigens / Q000032:analysis; D060908:CTLA-4 Antigen; D015316:Genetic Therapy; D006801:Humans; D018796:Immunoconjugates; D007167:Immunotherapy; D051379:Mice; D009369:Neoplasms / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D014162:Transfection
D015703:Antigens, CD; D000943:Antigens, Differentiation; D018122:B7-1 Antigen; D018106:CD28 Antigens; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; C556707:Ctla4 protein, mouse; D018796:Immunoconjugates; D000069594:Abatacept